There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen Inc (NASDAQ:AMGN) and Immunomedics (NASDAQ:IMMU) with bullish sentiments.
Amgen Inc (AMGN)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Amgen Inc today and set a price target of $206. The company’s shares opened today at $196.88, close to its 52-week high of $201.23.
According to TipRanks.com, Syed is a 4-star analyst with an average return of 7.7% and a 63.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Endo International, Wave Life Sciences, and Gilead Sciences.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $203.11.
See today’s analyst top recommended stocks >>
Immunomedics (IMMU)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Immunomedics, with a price target of $30. The company’s shares opened today at $21.48.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.3% and a 55.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunomedics with a $36 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
